Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M, Wu J, Ngo A, Manesh S, Tan E, Teh BT, So JB, Goh LK, Boussioutas A, Lim TK, Flotow H, Tan P, Rozen SG. Lei Z, et al. Among authors: pattison s. Gastroenterology. 2013 Sep;145(3):554-65. doi: 10.1053/j.gastro.2013.05.010. Epub 2013 May 14. Gastroenterology. 2013. PMID: 23684942
SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence.
Busuttil RA, George J, House CM, Lade S, Mitchell C, Di Costanzo NS, Pattison S, Huang YK, Tan P, Cheong JH, Rha SY, Boussioutas A. Busuttil RA, et al. Among authors: pattison s. Gastric Cancer. 2021 May;24(3):589-601. doi: 10.1007/s10120-020-01143-8. Epub 2020 Dec 4. Gastric Cancer. 2021. PMID: 33277667 Free PMC article.
A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer.
Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. Wang K, et al. Among authors: pattison s. Ther Adv Med Oncol. 2020 Jul 23;12:1758835920930359. doi: 10.1177/1758835920930359. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32754227 Free PMC article.
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, Jennens R, Clarke K, Pattison S, Burge M, Zielinski R, Nikfarjam M, Ananda S, Lipton L, Gibbs P, Lee B. Santucci J, et al. Among authors: pattison s. Eur J Cancer. 2022 Oct;174:102-112. doi: 10.1016/j.ejca.2022.06.042. Epub 2022 Aug 18. Eur J Cancer. 2022. PMID: 35988408
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Walpole I, Lee B, Shapiro J, Thomson B, Lipton L, Ananda S, Usatoff V, Mclachlan SA, Knowles B, Fox A, Wong R, Cooray P, Burge M, Clarke K, Pattison S, Nikfarjam M, Tebbutt N, Harris M, Nagrial A, Zielinski R, Chee CE, Gibbs P. Walpole I, et al. Among authors: pattison s. Asia Pac J Clin Oncol. 2023 Feb;19(1):214-225. doi: 10.1111/ajco.13807. Epub 2022 Jul 13. Asia Pac J Clin Oncol. 2023. PMID: 35831999
Bespoke treatment: drivers beware!
Pattison S, Zalcberg JR. Pattison S, et al. Asia Pac J Clin Oncol. 2014 Dec;10(4):378-80. doi: 10.1111/ajco.12265. Epub 2014 Aug 25. Asia Pac J Clin Oncol. 2014. PMID: 25155963
111 results